Investor Highlights 1. New Hedge fund investin
Post# of 30027
1. New Hedge fund investing directly into a side pocket investment for a public Biopharmaceutical company.
2. Grossly undervalued company (currently an $8mm market cap) of which independent analyst have all valued the company at over $150m.
3. Structured plan to remove the liability obstructing the company, which will give a clear path for appreciation.
4. Concise risk mitigation strategy.
5. Diverse product line in which the lead product has already been successfully used on over 130 humans of which the product had a 100% take rate for all patients who had received the product. The former president of the American Burn Association stated that in his opinion this product will cut the mortality rate in burn victims down by 50%!
Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
International Infusion is a leading venture capital firm dedicated to investing in disruptive technologies in the life sciences, renewable energy industries, and beyond.